Medpace Holdings, Inc. (MEDP) EV/EBIT Ratio: 22.58x
Is Medpace Holdings, Inc.’s EV/EBIT ratio high or low?
Medpace Holdings, Inc.'s EV/EBIT ratio of 22.58x is 20% below its 5-year average of 28.07x, near the low end of its 5-year range (18.61x–40.49x).
As of Thursday, June 18, 2026. 19.96% below its 12-month average of 28.21x.
MEDP EV/EBIT Ratio Chart
MEDP Average EV/EBIT Ratio Chart
MEDP Current vs Average EV/EBIT Ratio Chart
MEDP EV/EBIT Ratio Metrics
EV/EBIT RATIO
22.58x
EV/EBIT RATIO AVG TTM
28.21x
EV/EBIT RATIO AVG 3Y
28.08x
EV/EBIT RATIO AVG 5Y
28.07x
EV/EBIT RATIO AVG 10Y
28.04x
EV/EBIT RATIO AVG 15Y
N/A
EV/EBIT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-19.96%
CURRENT VS 3Y AVG
-19.58%
CURRENT VS 5Y AVG
-19.57%
CURRENT VS 10Y AVG
-19.47%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MEDP Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.04B | 22.58x | 28.21x | 28.08x | 28.07x |
| Align Technology, Inc. (ALGN)vs › | $13.04B | 20.45x | 19.27x | 26.31x | 31.20x |
| Solventum Corporation (SOLV)vs › | $12.97B | 8.34x | 20.62x | 17.31x | 17.31x |
| The Cooper Companies, Inc. (COO)vs › | $12.85B | 30.48x | 23.81x | 31.75x | 35.61x |
| DaVita Inc. (DVA)vs › | $13.34B | 12.91x | 11.82x | 13.00x | 13.13x |
| Revvity, Inc. (RVTY)vs › | $11.07B | 37.29x | 35.60x | 38.74x | 31.66x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | N/A | 25.59x | 34.39x | 25.01x |
| Baxter International Inc. (BAX)vs › | $10.29B | N/A | 442.63x | 243.35x | 134.31x |
| Hologic, Inc. (HOLX)vs › | $16.97B | 24.28x | 22.66x | 24.05x | 18.32x |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | 25.15x | 62.10x | 38.56x | 35.07x |
Medpace Holdings, Inc. EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for Medpace Holdings, Inc. (MEDP)?
- The EV/EBIT ratio for MEDP stock is 22.58x.
- Is Medpace Holdings, Inc.'s EV/EBIT ratio high or low?
- Medpace Holdings, Inc.'s EV/EBIT ratio of 22.58x is 20% below its 5-year average of 28.07x, near the low end of its 5-year range (18.61x–40.49x).
- What is the TTM average EV/EBIT ratio for Medpace Holdings, Inc. (MEDP)?
- The TTM average EV/EBIT ratio for MEDP stock is 28.21x.
- What is the 3Y average EV/EBIT ratio for Medpace Holdings, Inc. (MEDP)?
- The 3Y average EV/EBIT ratio for MEDP stock is 28.08x.
- What is the 5Y average EV/EBIT ratio for Medpace Holdings, Inc. (MEDP)?
- The 5Y average EV/EBIT ratio for MEDP stock is 28.07x.
- What is the 10Y average EV/EBIT ratio for Medpace Holdings, Inc. (MEDP)?
- The 10Y average EV/EBIT ratio for MEDP stock is 28.04x.
Medpace Holdings, Inc. EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-17 | 22.58x |
| 2026-06-16 | 22.81x |
| 2026-06-15 | 23.11x |
| 2026-06-12 | 23.10x |
| 2026-06-11 | 23.50x |
| 2026-06-10 | 23.02x |
| 2026-06-09 | 23.07x |
| 2026-06-08 | 22.62x |
| 2026-06-05 | 22.43x |
| 2026-06-04 | 22.66x |
| 2026-06-03 | 22.25x |
| 2026-06-02 | 21.98x |
| 2026-06-01 | 22.29x |
| 2026-05-29 | 22.06x |
| 2026-05-28 | 22.11x |
| 2026-05-27 | 21.08x |
| 2026-05-26 | 21.14x |
| 2026-05-22 | 21.33x |
| 2026-05-21 | 21.19x |
| 2026-05-20 | 20.76x |
| 2026-05-19 | 20.66x |
| 2026-05-18 | 20.70x |
| 2026-05-15 | 20.42x |
| 2026-05-14 | 20.62x |
| 2026-05-13 | 20.86x |
| 2026-05-12 | 20.65x |
| 2026-05-11 | 20.53x |
| 2026-05-08 | 20.87x |
| 2026-05-07 | 21.11x |
| 2026-05-06 | 21.02x |
| 2026-05-05 | 21.20x |
| 2026-05-04 | 20.51x |
| 2026-05-01 | 20.54x |
| 2026-04-30 | 20.60x |
| 2026-04-29 | 20.34x |
| 2026-04-28 | 20.13x |
| 2026-04-27 | 20.74x |
| 2026-04-24 | 20.18x |
| 2026-04-23 | 19.30x |
| 2026-04-22 | 27.07x |
| 2026-04-21 | 27.42x |
| 2026-04-20 | 28.15x |
| 2026-04-17 | 27.73x |
| 2026-04-16 | 27.46x |
| 2026-04-15 | 27.62x |
| 2026-04-14 | 27.69x |
| 2026-04-13 | 26.68x |
| 2026-04-10 | 26.26x |
| 2026-04-09 | 26.69x |
| 2026-04-08 | 27.73x |
| 2026-04-07 | 27.07x |
| 2026-04-06 | 26.39x |
| 2026-04-02 | 26.52x |
| 2026-04-01 | 26.04x |
| 2026-03-31 | 25.54x |
| 2026-03-30 | 24.46x |
| 2026-03-27 | 23.97x |
| 2026-03-26 | 24.80x |
| 2026-03-25 | 24.81x |
| 2026-03-24 | 24.49x |
| 2026-03-23 | 24.28x |
| 2026-03-20 | 24.04x |
| 2026-03-19 | 24.50x |
| 2026-03-18 | 24.16x |
| 2026-03-17 | 24.18x |
| 2026-03-16 | 24.10x |
| 2026-03-13 | 23.93x |
| 2026-03-12 | 23.57x |
| 2026-03-11 | 25.41x |
| 2026-03-10 | 24.81x |
| 2026-03-09 | 25.45x |
| 2026-03-06 | 25.02x |
| 2026-03-05 | 24.95x |
| 2026-03-04 | 24.76x |
| 2026-03-03 | 24.74x |
| 2026-03-02 | 24.31x |
| 2026-02-27 | 24.00x |
| 2026-02-26 | 23.75x |
| 2026-02-25 | 23.26x |
| 2026-02-24 | 23.48x |
| 2026-02-23 | 23.63x |
| 2026-02-20 | 24.11x |
| 2026-02-19 | 23.71x |
| 2026-02-18 | 23.70x |
| 2026-02-17 | 22.72x |
| 2026-02-13 | 22.71x |
| 2026-02-12 | 22.07x |
| 2026-02-11 | 22.49x |
| 2026-02-10 | 23.69x |
| 2026-02-09 | 30.80x |
| 2026-02-06 | 31.48x |
| 2026-02-05 | 31.44x |
| 2026-02-04 | 32.62x |
| 2026-02-03 | 33.03x |
| 2026-02-02 | 34.18x |
| 2026-01-30 | 33.85x |
| 2026-01-29 | 34.47x |
| 2026-01-28 | 34.76x |
| 2026-01-27 | 35.01x |
| 2026-01-26 | 35.00x |
| 2026-01-23 | 34.18x |
| 2026-01-22 | 35.25x |
| 2026-01-21 | 36.08x |
| 2026-01-20 | 35.02x |
| 2026-01-16 | 35.52x |
| 2026-01-15 | 35.93x |
| 2026-01-14 | 35.84x |
| 2026-01-13 | 35.37x |
| 2026-01-12 | 34.83x |
| 2026-01-09 | 34.58x |
| 2026-01-08 | 34.88x |
| 2026-01-07 | 35.64x |
| 2026-01-06 | 35.40x |
| 2026-01-05 | 34.11x |
| 2026-01-02 | 33.18x |
| 2025-12-31 | 32.63x |
| 2025-12-30 | 33.05x |
| 2025-12-29 | 33.12x |
| 2025-12-26 | 32.98x |
| 2025-12-24 | 33.23x |
| 2025-12-23 | 33.10x |
| 2025-12-22 | 33.21x |
| 2025-12-19 | 33.02x |
| 2025-12-18 | 32.55x |
| 2025-12-17 | 32.36x |
| 2025-12-16 | 32.46x |
| 2025-12-15 | 32.48x |
| 2025-12-12 | 32.41x |
| 2025-12-11 | 32.89x |
| 2025-12-10 | 32.58x |
| 2025-12-09 | 31.60x |
| 2025-12-08 | 31.90x |
| 2025-12-05 | 31.84x |
| 2025-12-04 | 31.64x |
| 2025-12-03 | 33.50x |
| 2025-12-02 | 33.92x |
| 2025-12-01 | 34.17x |
| 2025-11-28 | 34.44x |
| 2025-11-26 | 35.26x |
| 2025-11-25 | 35.57x |
| 2025-11-24 | 35.96x |
| 2025-11-21 | 34.40x |
| 2025-11-20 | 34.07x |
| 2025-11-19 | 34.42x |
| 2025-11-18 | 34.30x |
| 2025-11-17 | 34.04x |
| 2025-11-14 | 34.30x |
| 2025-11-13 | 34.37x |
| 2025-11-12 | 34.74x |
| 2025-11-11 | 35.04x |
| 2025-11-10 | 34.90x |
| 2025-11-07 | 34.24x |
| 2025-11-06 | 34.42x |
| 2025-11-05 | 34.81x |
| 2025-11-04 | 34.56x |
| 2025-11-03 | 34.53x |
| 2025-10-31 | 33.99x |
| 2025-10-30 | 33.73x |
| 2025-10-29 | 33.97x |
| 2025-10-28 | 33.74x |
| 2025-10-27 | 34.67x |
| 2025-10-24 | 35.18x |
| 2025-10-23 | 34.68x |
| 2025-10-22 | 34.76x |
| 2025-10-21 | 34.69x |
| 2025-10-20 | 34.61x |
| 2025-10-17 | 33.58x |
| 2025-10-16 | 33.14x |
| 2025-10-15 | 32.71x |
| 2025-10-14 | 32.87x |
| 2025-10-13 | 33.53x |
| 2025-10-10 | 31.88x |
| 2025-10-09 | 32.98x |
| 2025-10-08 | 33.76x |
| 2025-10-07 | 33.81x |
| 2025-10-06 | 33.72x |
| 2025-10-03 | 33.85x |
| 2025-10-02 | 34.09x |
| 2025-10-01 | 34.58x |
| 2025-09-30 | 32.70x |
| 2025-09-29 | 31.85x |
| 2025-09-26 | 31.60x |
| 2025-09-25 | 31.04x |
| 2025-09-24 | 31.63x |
| 2025-09-23 | 31.56x |
| 2025-09-22 | 31.68x |
| 2025-09-19 | 31.71x |
| 2025-09-18 | 31.93x |
| 2025-09-17 | 31.67x |
| 2025-09-16 | 31.22x |
| 2025-09-15 | 31.58x |
| 2025-09-12 | 31.21x |
| 2025-09-11 | 31.65x |
| 2025-09-10 | 30.33x |
| 2025-09-09 | 30.89x |
| 2025-09-08 | 31.30x |
| 2025-09-05 | 30.98x |
| 2025-09-04 | 30.69x |
| 2025-09-03 | 30.62x |
| 2025-09-02 | 30.12x |
| 2025-08-29 | 30.26x |
| 2025-08-28 | 30.09x |
| 2025-08-27 | 30.13x |
| 2025-08-26 | 29.86x |
| 2025-08-25 | 29.71x |
| 2025-08-22 | 29.51x |
| 2025-08-21 | 28.85x |
| 2025-08-20 | 29.64x |
| 2025-08-19 | 29.41x |
| 2025-08-18 | 29.46x |
| 2025-08-15 | 29.14x |
| 2025-08-14 | 29.19x |
| 2025-08-13 | 29.78x |
| 2025-08-12 | 29.23x |
| 2025-08-11 | 28.63x |
| 2025-08-08 | 27.66x |
| 2025-08-07 | 27.30x |
| 2025-08-06 | 27.40x |
| 2025-08-05 | 27.78x |
| 2025-08-04 | 27.53x |
| 2025-08-01 | 26.94x |
| 2025-07-31 | 27.20x |
| 2025-07-30 | 27.87x |
| 2025-07-29 | 28.51x |
| 2025-07-28 | 28.84x |
| 2025-07-25 | 28.49x |
| 2025-07-24 | 29.00x |
| 2025-07-23 | 27.85x |
| 2025-07-22 | 30.40x |
| 2025-07-21 | 20.43x |
| 2025-07-18 | 20.63x |
| 2025-07-17 | 21.13x |
| 2025-07-16 | 20.83x |
| 2025-07-15 | 20.69x |
| 2025-07-14 | 21.21x |
| 2025-07-11 | 21.43x |
| 2025-07-10 | 21.75x |
| 2025-07-09 | 21.25x |
| 2025-07-08 | 21.36x |
| 2025-07-07 | 21.11x |
| 2025-07-03 | 21.29x |
| 2025-07-02 | 21.60x |
| 2025-07-01 | 21.26x |
| 2025-06-30 | 20.77x |
| 2025-06-27 | 20.55x |
| 2025-06-26 | 20.28x |
| 2025-06-25 | 20.58x |
| 2025-06-24 | 20.86x |
| 2025-06-23 | 20.41x |
| 2025-06-20 | 20.46x |
| 2025-06-18 | 20.00x |
| 2025-06-17 | 19.68x |
| 2025-06-16 | 19.89x |
| 2025-06-13 | 19.70x |
| 2025-06-12 | 20.09x |
| 2025-06-11 | 19.98x |
| 2025-06-10 | 20.22x |
| 2025-06-09 | 19.70x |
| 2025-06-06 | 19.58x |
| 2025-06-05 | 19.38x |
Showing the most recent 260 of 2,476 data points. The chart above shows the full history.
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle